Galectin Therapeutics Offers Update At Annual Meeting: CEO Reviews Results Of NASH-CX Trial Which Showed Statistically Significant, Clinically Meaningful Effects In Patients Who Had NASH Cirrhosis But Did Not Have Esophageal Varices